Jupiter Neurosciences (NASDAQ:JUNS) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Jupiter Neurosciences (NASDAQ:JUNS) announced its earnings results on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01), FiscalAI reports. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.23 million.

Jupiter Neurosciences Price Performance

Shares of JUNS stock traded down $0.01 on Friday, reaching $0.34. 40,053 shares of the company were exchanged, compared to its average volume of 88,968. The company has a market cap of $12.26 million, a price-to-earnings ratio of -1.25 and a beta of 2.16. The company has a 50-day moving average of $0.38 and a 200-day moving average of $0.78. Jupiter Neurosciences has a one year low of $0.31 and a one year high of $3.33.

Hedge Funds Weigh In On Jupiter Neurosciences

A hedge fund recently raised its stake in Jupiter Neurosciences stock. Geode Capital Management LLC lifted its stake in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 27.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,641 shares of the company’s stock after purchasing an additional 28,826 shares during the quarter. Geode Capital Management LLC owned about 0.39% of Jupiter Neurosciences worth $135,000 at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.